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Abstract
Background:  Thalidomide is an immunomodulatory agent, which arrests angiogenesis. The
mechanism of anti-angiogenic activity of thalidomide is not fully understood. As nitric oxide is
involved in angiogenesis, we speculate a cross-talk between thalidomide and nitric oxide signaling
pathway to define angiogenesis. The aim of present study is to understand the mechanistic aspects
of thalidomide-mediated attenuation of angiogenesis induced by nitric oxide at the cellular level.
Methods: To study the cellular mechanism of thalidomide-mediated blocking of angiogenesis
triggered by nitric oxide, we used two endothelial cell based models: 1) wound healing and 2) tube
formation using ECV 304, an endothelial cell line. These cell-based models reflect pro-angiogenic
events in vivo. We also studied the effects of thalidomide on nitric oxide mediated egg yolk
angiogenesis. Thalidomide could block the formation of blood vessels both in absence and presence
of nitric oxide. Thalidomide effects on migration of, and actin polymerization in, ECV 304 cells were
studied at the single cell level using live cell imaging techniques and probes to detect nitric oxide.
Results: Results demonstrate that thalidomide blocks nitric oxide-mediated angiogenesis in egg
yolk model and also reduces the number of tubes formed in endothelial cell monolayers. We also
observed that thalidomide arrests wound healing in presence and absence of nitric oxide in a dose-
dependent fashion. Additionally, thalidomide promotes actin polymerization and antagonizes the
formation of membrane extensions triggered by nitric oxide in endothelial cells. Experiments
targeting single tube structure with thalidomide, followed by nitric oxide treatment, show that the
tube structures are insensitive to thalidomide and nitric oxide. These observations suggest that
thalidomide interferes with nitric oxide-induced migration of endothelial cells at the initial phase of
angiogenesis before cells co-ordinate themselves to form organized tubes in endothelial cells and
thereby inhibits angiogenesis.
Conclusion:  Thalidomide exerts inhibitory effects on nitric oxide-mediated angiogenesis by
altering sub-cellular actin polymerization pattern, which leads to inhibition of endothelial cell
migration.
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Background
Thalidomide,  α-(N-phthalimido) glutarimide is an
immunomodulatory agent, which is used as a drug to treat
multiple myeloma and other types of cancers [1]. The
drug thalidomide, first synthesized in 1954 [2,3], was
widely prescribed to treat morning sickness in pregnant
women in the early 60s. However, thalidomide became
anathema when it was found to be seriously teratogenic
having caused serious birth defects in more than 10,000
newborns. It was subsequently banned in Europe. As sci-
entists probed further into the causes for teratogenicity,
they realized the innate potency of this drug to treat other
diseases [4]. Now, a quarter of a century later, it appears
that it may be a miracle drug for such diseases as cancer,
AIDS and SLE. In August 1998, Food and Drug Adminis-
tration (FDA) approved Thalidomide for sale in the USA
for chronic treatment of erythema nodosum leprosum
(ENL), a painful inflammatory dermatological reaction of
lepromatous leprosy [4].
Thalidomide has anti-angiogenic properties that are inde-
pendent of its immunomodulatory effects [5,6]. Its
involvement in angiogenesis is being studied extensively
as angiogenesis is one of the most important develop-
ments in metastazing tumors. Thalidomide has been
shown to inhibit the expression of vascular endothelial
growth factor (VEGF) and IL-6, which is believed to be the
mechanism for the attenuation of angiogenesis by thalid-
omide [7]
Nitric oxide (NO), produced by the enzyme nitric oxide
synthase (NOS), an important second messenger in many
signaling pathways, is a potent vasodilator [8]. NO is pro-
duced by the action of NOS in the transformation of
arginine to citrulline and activates soluble guanylate
cyclase to produce cGMP [9]. NO is involved in angiogen-
esis and endothelial cells (EC) migration [10]. Recent
publications suggest that endothelial-derived NO is
required for Ang1-induced angiogenesis and that the PI3-
kinase signaling mediates the activation of eNOS and NO
release in response to Ang1 [11]. NO is also instrumental
in promoting Ang1-induced angiogenesis in combination
with HSP90 and Akt in coronary artery endothelium [12].
As thalidomide interferes with angiogenesis, a process in
which NO also plays a crucial role, we speculate a cross
talk between thalidomide and NO signaling pathway.
Currently, the involvement and interaction of thalido-
mide and the NO signaling pathway is not known. The
mechanistic aspects of thalidomide action need to be elu-
cidated further. The aim of present work was to study the
mechanistic aspects of the attenuation of NO-driven ang-
iogenesis due to thalidomide at the cellular level. Our
study indicates that thalidomide attenuates NO-driven
angiogenesis by blocking migration of ECs even before
any tube structure had been formed, which further hints
an interaction between thalidomide and NO signaling.
Methods
Materials
Dulbecco's modified Eagle's medium (DMEM), from Hi-
Media, Mumbai, India. Fetal bovine serum (FBS) was
from Invitrogen Life technologies (Gaithersburg, MD).
Thalidomide was purchased from Sigma Chemical Co (St.
Louis, MO), and phalloidin Alexa Fluor 568 (phalloidin)
from Molecular Probes (Portland, OR, USA). All other
chemicals were at least of the reagent grade.
Cell culture
Human umbilical vein endothelial cells (ECV 304) were
cultured in DMEM supplemented with 10 % FBS (v/v)
and 1% penicillin (w/v) and streptomycin (w/v).
Endothelial tube formation assay
ECV 304 cells were seeded on collagen (collagen type I)
plated 12-well plates with 60% cell density. After 7 hours
of incubation, 500 µmol of sodium nitroprusside (SNP),
a NO donor, was added to the cells. After another 17 hour
period, cells were treated with thalidomide at different
concentrations (50, 100 and 150 µg/ml) and incubated
for 8 hours. All the incubations were performed in an
incubator at 37°C and under 5% CO2  95% air. The
number of tubes was counted under bright field phase
contrast microscope. Only the complete ring structures
created by 3 to 5 ECs were counted as tubes.
Single cell migration assay
Cell migration was assessed by a wound healing method
[10]. One million ECV 304 cells in 2 ml of DMEM/10%
FBS were seeded in a 35 mm dish. Twenty-four hours
later, when the cells reached confluence, a linear wound
was made by scratching the monolayer with a 1 mm wide
sterile plastic scraper. As per the experimental protocol
described elsewhere [10], cells were washed with PBS,
treated with SNP (500 µmol) and incubated for a fixed
time period (8 hours unless otherwise stated) with and
without thalidomide at different concentrations. Light
microscopy images were taken with 10× and 40× magnifi-
cations.
Boyden's chamber based migration assay
Trypsinized ECV 304 cells were used for migration assay
using Boyden's chamber, which is a two-chamber system.
The upper and lower chambers are separated by a collagen
coated 8-µm pore size polycarbonate membranes. ECV
304 cells were loaded in the upper well with thalidomide
alone or thalidomide plus SNP. Lower well was filled with
DMEM. The chambers were then incubated at 37°C, 5%
CO2 for 3 hours. Cells were migrated across the mem-
brane and stuck to the lower part of the membrane. AfterBMC Cell Biology 2006, 7:17 http://www.biomedcentral.com/1471-2121/7/17
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the incubation, the polycarbonate membrane was fixed
and stained with propidium iodide, a fluorescent nuclear
probe. Endothelial cell migration activity was quantified
as the number of migrated cells on the lower surface of the
membrane. Cell number was counted before and after
experiments to quantify the proliferation status of the
loaded cells in Boyden's chamber.
Egg yolk angiogenesis assay
Fourth day incubated eggs were collected from the Poultry
Research Station, Nandanam, Chennai. Eggs were broken
and gently plated on a cellophane bed in Petri dishes
under sterile conditions. Egg yolks were incubated with
500 µmol SNP on a filter paper disc for 6 hours. Thalido-
mide discs (25, 50,75 µg/ml) were then placed on the egg
yolks and were incubated for another 6 hours. Images
were taken using a Kodak digital camera at 0, 6 and 12
hours of incubation. Quantification of angiogenesis was
performed by using Scion Image, Release Alpha 4.0 3.2
and Adobe Photoshop version 6.0.
Fluorescence microscopy
ECV 304 cells were cultured on cover glasses in 12-well
plates till they reach 40% confluency before starting the
experiments. ECV 304 cells were incubated with 500 µmol
SNP for 15 minutes. Next, thalidomide was added at dif-
Thalidomide blocks angiogenesis Figure 1
Thalidomide blocks angiogenesis. Fourth day incubated chicken eggs were broken, entire egg contents were transferred 
into a sterile petri dish. In vascular bed, heart and blood capillary are visible on 0 hour panel (left). Next, the vascular bed was 
incubated with 100 µg/ml thalidomide disc, placed on the vascular bed for 12 hours. It is evident from the representative 
images that 100 µg/ml thalidomide retarded the growth of the blood capillaries at the edges of vascular bed. A 70% loss of 
blood vessels (inset on top of the panels) was estimated by counting the number of red pixels using an analytical module of 
Adobe Photoshop ver. 6.0.
 Tx
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ferent concentrations (25, 50, 75 µg/ml) to the cells. After
15 minutes of incubation at 37°C, the cover slips were
washed gently with PBS and cells were fixed in 2% para-
formaldehyde for 7 minutes, permeabilized with 0.1%
Triton X -100 for 2 minutes and incubated with phalloi-
din alexa fluor 568 (phalloidin) (0.5 µM final concentra-
tion) for 1 hour. The fluorescence of phalloidin bound to
F-actin was viewed under NIKON TE2000-U fluorescent
microscope at 560 nm emission. Photographs were taken
with an Andor CCD camera attached to the microscope.
Statistical analysis
Data is presented as mean + SE. Data was analyzed using
paired and unpaired Student's t-tests as appropriate. A P
value smaller or equal to 0.05 was selected as a criterion
for a statistically significant difference.
Results
Thalidomide blocks angiogenesis
An egg yolk vascular bed model is an angiogenesis model
in which one can track and observe the development of
cardiovascular system including angiogenesis [13]. This
model was chosen for our experiments to test the effects
of thalidomide on angiogenesis. Yolks from the 4th day-
fertilized eggs with semi-developed vascular bed were
plated on petri dishes and treated with thalidomide (50,
100, 150 µg/ml) for 12 hours. Egg yolk vascular beds
treated with 150 µg/ml thalidomide showed necrotic
effects on vascular bed (images not shown) while vascular
beds treated with 50 and 100 µg/ml of Thalidomide were
healthier. Capillary growth was significantly inhibited by
thalidomide without disturbing other vasculature (Figure
1). A 12-hour treatment with thalidomide (100 µg/ml)
caused a 70% loss in terminal capillaries in the egg yolk
vascular bed (Figure 1).
Thalidomide attenuates tube formation in EC monolayer
To explore the effects of thalidomide on endothelial func-
tions, we used two cell-based models, tube formation and
wound healing, in monolayer cultures of immortalized
ECV 304 cells. ECs have natural tendency to organize
themselves to form three-dimensional structures (tube
formation) in monolayer culture [14]. We checked the
effects of thalidomide on tube formation after 12 hours of
incubation and observed a dose-dependent reduction in
the number of tubes formed (Figure 2).
Thalidomide arrests wound healing in EC monolayer
The wound healing model is used to estimate the migra-
tion potential of the ECs in monolayer culture [15].
Wounds were artificially made in EC monolayer before
addition of thalidomide (50, 100 and 150 µg/ml) and
incubation for another 8 hours (Figure 3). Thalidomide
Thalidomide impairs basal wound healing in EC monolayer Figure 3
Thalidomide impairs basal wound healing in EC mon-
olayer. Wound was created with a sterile plastic scraper 
and images were taken at 0 and 8 hours. A representative 
image from top panel shows how the proliferation of ECs 
heal the wound in 8 hours. The rate of wound healing was 
quantified (in the graph below) from the images using Scion 
Image, Release Alpha 4.0 3.2 and Adobe Photoshop version 
6.0. Analysis of the data depicts that the rate of wound heal-
ing is slower in 100 and 150 µg/ml thalidomide treated cells. 
The asterisks represent the level of significance. * P < 0.05 
compared to control.
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Thalidomide attenuates tube formation in ECs Figure 2
Thalidomide attenuates tube formation in ECs. 
Trypsinized ECs in suspension culture were seeded on colla-
gen coated 12 well plates with 70%cell density. After 24 
hours, the ECs were treated with different concentrations of 
thalidomide, (50, 100 and 150 µg/ml) and incubated at 37°C/
5%CO2 for 12 hours and thereafter, total number of tubes 
were counted. Number of tubes was reduced in all, 50 100 
and 150µg/ml thalidomide treated ECs respectively.
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caused 20 % and 10% reduction in the rate of wound
healing at 150 and 100 µg/ml respectively but had no
effect at the lowest concentration (50 µg/ml) used (Figure
3). Additionally, a drastic change in morphology, charac-
terized by the rounding up of 30% of total cell population
but no loss of viability (data not shown), was observed in
cells submitted to thalidomide at 150 µg/ml. Because this
was not an expected phenomenon in angiogenesis in vivo,
lower concentrations (25, 50 and 75 µg/ml) were tested.
Further, we performed trypan blue viability assay on tha-
lidomide (25, 50 and 75 µg/ml) treated ECs. Results
showed that thalidomide does not interfere with the via-
bility of ECs (data not shown). A simultaneous close cap-
ture of the edges of the artificially created wounds was
used to obtain information about migration at the single
cell level (Figure 4). Thalidomide mostly at 50 (data not
shown) and 75 µg/ml, antagonized membrane extensions
in ECs and probably thereby reduced the rate of migration
of the cells at the wound edges (Figure 4).
Thalidomide induces cytoskeletal rearrangements in ECs
Recent evidence suggest that thalidomide is involved in
cell migration, development and morphology as observed
with the mesenchymal neural crest cells, which are the
developmental precursors of the corneal endothelium
and stroma [16]. Thalidomide appears to predominantly
inhibit leukocyte rolling which suggests that the inhibi-
tion of LPS- or muTNF-alpha-induced leukocyte extrava-
sation by thalidomide may account for some of its clinical
activities [17]. We treated ECV 304 cells with thalidomide
at concentrations (25, 50 and 75 µg/ml) that did not affect
cell viability (data not shown) for 30 minutes. Cells were
then stained with phalloidin, a water-soluble compound
that selectively binds with F-actin at nanomolar concen-
trations [18]. Thalidomide, at 75 µg/ml, induced the for-
mation of central microfilaments (Figure 5, arrows,
thalidomide +) and reduced the number of lamellipodia,
in comparison to what was observed in control cells
treated with DMSO (solvent for thalidomide) (Figure 5,
arrows, thalidomide -). Furthermore, we observed that
central microfilaments in thalidomide-treated cells pre-
sented a thick, medium thick or a thin centre (Figure 5).
Next, similar experiments were performed using cell dou-
blets where two ECV 304 cells are attached at the cell-cell
interface. The representative image (Figure 6) indicates
that a treatment with thalidomide at 75 µg/ml prevented
the formation of lamellipodia extensions on the cell sur-
face and induced actin polymerization to form central
microfilaments (Figure 6). Cell-cell communication is an
essential part for ECs to tune signal transduction to con-
trol cellular migration, proliferation and angiogenesis [8].
To understand the effects of thalidomide on actin polym-
erization at the cell-cell interface we treated EC doublets
with thalidomide and observed a drastic drop in the
Cytoskeletal rearrangements by thalidomide Figure 5
Cytoskeletal rearrangements by thalidomide. ECs 
were treated with different doses of thalidomide (25, 50 and 
75 µg/ml). Representativeimage of ECs treated with 75 µg/ml 
thalidomide, depicts that thalidomide induces central micro 
filaments (arrows, thalidomide +) and reduces the number of 
lamellipodia in comparison to the control cell treated with 
DMSO, the vehicle only (arrows, thalidomide -). Further, we 
observed three sub populations of the central microfilaments 
in thalidomide treated cells, thick (thicker broken arrow), 
medium thick (thin broken arrow) and a thin centre microfil-
ament (arrow head).
Thalidomide (75 µg/ml)
-+
Thalidomide attenuates NO mediated migration in ECs Figure 4
Thalidomide attenuates NO mediated migration in 
ECs: After the wound was created in confluent ECs, they 
were treated with 500µM SNP (NO donor) and incubated 
for 15 minutes at 37°C/5% CO2. Next, the cells were treated 
with 75 µg/ml thalidomide and incubated for another 15 min-
utes. Images of the wound-edge were taken at 0 minutes, 15 
minutes and 30 minutes with a 40× magnification objective 
lens mounted on Nikon TE2000-U inverted microscope. 
Arrows indicate the growing phases of the wounds after 15 
minutes of incubation with SNP. Arrows in the middle panel 
indicates the growing phase of ECs under thalidomide treat-
ment, while thalidomide arrests the SNP mediated migration 
of the cells after 15 minutes of thalidomide treatments (white 
arrows in the right panel).
Time (mins)                                0 15             30
SNP +                              +                              +
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degree of actin polymerization at the cell-cell interface
(Figure 6).
Thalidomide attenuates NO-mediated angiogenesis in egg 
yolk models and tube formation in EC monolayers
Thalidomide interferes with angiogenesis in egg yolk vas-
cular bed models (Figure 1). Using the same experimental
design, egg yolk vascular beds were first treated with SNP
for 6 hours to induce angiogenesis and then with thalido-
mide (25, 50 and 75µg/ml). Representative images (figure
7) are blocks of 0.5 cm × 1 cm. from the whole vascular
bed. SNP promoted the formation of new blood vessels
and thalidomide arrested NO-mediated blood vessel for-
mation at the growing edges of vasculature even though
no dose-dependency could be evidenced (Figure 7). The
effect of thalidomide was also tested on NO-mediated
tube formation in EC monolayer. The cellular unit of ang-
iogenesis is considered to be the tube structures formed in
the EC monolayer [19]. NO-mediated tube formation was
reduced by 43% and 40% in cells treated with 50 and 75
µg/ml thalidomide respectively (Figure 8). Thalidomide
was also applied to individual tube structures, complete
or incomplete, for 15 minutes followed by SNP treatment
for another 15 minutes. Cells participating in the tube for-
mation responded to thalidomide challenge and showed
membrane activities such as the formation of membrane
extensions (Figure 10). Simultaneously, another NO
donor, DEA- NONOate (DEAN), was used to induce tube
formation in EC monolayer to verify the specificity of NO
effects. A concentration of 10 µmol DEAN caused 20%
increase in the number of tubes formed in EC monolayer.
All three concentrations of thalidomide (25, 50 and 75µg/
ml) attenuated DEAN induced tube formation in EC
monolayer (Figure 9). However, cells present in complete
tubes did not respond to thalidomide or SNP at any con-
centration. Both the luminal and external sides of the cells
present in the tube were smooth and static in response to
thalidomide treatments followed by SNP challenge (Fig-
ure 10).
Thalidomide arrests NO mediated wound healing in ECs
Thalidomide appears to slow down the rate of wound
healing in EC (Figure 3). Thalidomide may also modulate
NO-mediated wound healing in EC monolayer since this
substance attenuated the rate of migration and slowed
down the wound healing process triggered with SNP. Tha-
Thalidomide attenuates NO mediated blood capillaries in inv- itro egg yolk angiogenesis Figure 7
Thalidomide attenuates NO mediated blood capillar-
ies in invitro egg yolk angiogenesis. Fourth day incu-
bated chicken eggs were broken, entire egg contents were 
transferred in sterilized petri dish and their vascular beds 
were treated with 500 µM SNP and incubated at 37°C/5% 
CO2 for 6 hours. Next, different (25, 50, and 75 µg/ml) con-
centrations of thalidomide was added to SNP treated vascu-
lar beds respectively and incubated for another 6 hours. 
Images were taken at 0 hours, 6 hours and 12 hours that 
show that SNP promoted blood vessel formation in the vas-
cular bed in 6 hours (indicated by arrows). All the three con-
centrations of thalidomide were found to retard SNP 
mediated growth of blood capillaries at the end of 12 hours 
incubation.
25 µg/ml
75 µg/ml
SNP
Thalidomide
+ (0hrs)          + (6hrs)                 + (12hrs)
- + (0hrs)                 + (6hrs)
50 µg/ml
Thalidomide
Thalidomide induced a sharp fall in actin polymerization pat- tern at the cell-cell interface Figure 6
Thalidomide induced a sharp fall in actin polymeriza-
tion pattern at the cell-cell interface. ECs doublets 
were treated with and without thalidomide respectively, as 
described elsewhere. A representative image of the ECs 
treated with 75 µg/ml thalidomide demonstrates a drastic 
drop in the degree of actin polymerization at the cell-cell 
interface, and that the arrays of stress fibers are formed 
under thalidomide challenge in ECs (see boxes in the images, 
figure 3b).
Thalidomide (75 µg/ml)
-+BMC Cell Biology 2006, 7:17 http://www.biomedcentral.com/1471-2121/7/17
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lidomide at 50 and 75 µg/ml slowed down the NO medi-
ated wound healing in ECs by 50% and 80% respectively
(Figure 11).
Thalidomide antagonizes the formation of SNP induced 
lamellipodia and filopodia
The known anti-angiogenic effects of thalidomide might
be attributed to its anti-migratory effects [20,21]. Because
no detailed study has been performed so far to understand
the anti-migratory effects of thalidomide at the cellular
level, we studied the pattern of actin polymerization in
ECs treated with SNP and SNP plus thalidomide. SNP
induced the formation of filopodia and lamellipodia in
EC membrane while subsequent treatments with thalido-
mide (25, 50 and 75 µg/ml) either inhibited the forma-
tion or reduced the number of filopodia and lamellipodia
on the EC surface (data not shown).
Further analysis of the images obtained from the experi-
ments described above shows the combination effects of
thalidomide and SNP on the migratory pattern of ECV
304 cells. SNP treatments marginally increased the area of
the cells, an effect that was accentuated by subsequent
addition of thalidomide (25, 50 and 75 µg/ml) (Figure
12). Accordingly a dose-dependent increase in the perim-
eter of the cells treated with SNP plus thalidomide was
recorded (data not shown). Furthermore, the number of
lamellipodia was increased in SNP-treated cells but
decreases when thalidomide, at 50 and 75 µg/ml, was
used in combination (Figure 13). Similar effects of SNP
and thalidomide were observed when cells were analyzed
for filopodia and stress fibers formation (Figure 13 and
14).
Thalidomide arrests SNP induced migration of ECs
Boyden's chamber set up was employed to measure the
collective migration pattern of ECs under SNP and SNP +
thalidomide treatments. Analysis of Boyden's chamber
experiments shows that all the concentrations of thalido-
mide arrested completely the SNP induced migration of
ECs (Figure 15). Cell count remained same before and
after the experiments, which further proves that thalido-
mide interferes with SNP mediated migration of ECs.
Thalidomide reduces sub-population of the SNP treated 
cells with highermembrane actin polymerization pattern
Analysis of the images obtained from phalloidin experi-
ments indicates that cells are divided into two sub-popu-
lations with low actin polymerization (low AP) and high
actin polymerization (high AP) in relation to fluorescence
intensity (Figure 16). SNP treatments of ECs caused an
increase in the number of high AP cells, an effect that was
reversed by thalidomide (25, 50 and 75 µg/ml) in a dose-
dependent manner. The reduction of the high AP popula-
tion was associated with a corresponding increase in low
AP cells (figure 16).
Thalidomide attenuates DEAN induced tube formation in  ECs Figure 9
Thalidomide attenuates DEAN induced tube forma-
tion in ECs. ECs were seeded on collagen plated 12 well 
plates with 60% cell density, to form monolayers after 24 
hours of incubation at 37°C/5% CO2. Total number of 
DEAN (10 µmol) induced tubes were counted after 12 hours 
of incubation with thalidomide (25, 50, and 75 µgm/ml). * P < 
0.05 compared to only DEAN treated cells.
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Thalidomide attenuates tube formation in ECs Figure 8
Thalidomide attenuates tube formation in ECs. ECs 
were seeded on collagen coated 12 well plates with 60% cell 
density, induced with SNP (500 µmol) and incubated at 
37°C/5% CO2 for 24 hours. A reduction inthe number of 
NO mediated tubes has been observed by 43% and 40% in 50 
and 75 µg/ml thalidomide treated cells respectively.
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Discussion
In 1994, an ophthalmologist at Harvard Medical School
discovered that thalidomide inhibits angiogenesis when
tissues become deficient in oxygen [22]. The specific
mechanism by which thalidomide inhibits angiogenesis
is, as of yet, not known [23]. In our present work, we
tested the anti-angiogenic potential of thalidomide by
using egg yolk vascular bed. Results indicate that thalido-
mide blocks growth of the blood vessels at the periphery
of the vascular bed (figure 1). We speculate that thalido-
mide affect the EC migration to attenuate angiogenesis at
the cellular level. Thalidomide is also involved in the
process of inflammation [24, 25, and 26]. Inflammation
and cellular migration are two indispensable cellular
mechanisms that complement each other [27]. Through
experimentation in rabbits and in doing case studies on
people being treated with thalidomide, researchers deter-
mined that thalidomide modulates the production of the
inflammatory cytokine, TNF [23]. TNF-alpha is a cytokine
produced by immune cells in the blood stream that acts as
pro-angiogenic factor [28]. Thalidomide inhibits TNF-
alpha by amplifying the degradation of messenger RNA
(mRNA), and decreases the production of interleukin-12,
which is involved in immunity responses, the stimulation
of inflammation, and suppression of certain cytokines
[29-31]. From these observations we delineate an associa-
tion between cellular migration and thalidomide actions
in ECs.
Our present work documents that thalidomide attenuates
basal and NO-mediated EC migration in a dose-depend-
ent manner (figure 3, 4, 9). Hence, in addition to NO sig-
naling thalidomide appears to affect the migratory pattern
of ECs by interfering other signaling pathway/s as well.
Contrary to our assumption, single tube structure in the
monolayer of ECs was resistant to thalidomide and SNP
treatment in short-term experimental models (figure 10).
We can speculate that the level of maturity of tubes is
important for the effects of SNP and thalidomide as our
results showed that nascent tubes were resistant to the
effects of thalidomide (figure 10). Experiments in which
phalloidin labeling of actin was performed indicate that
thalidomide inhibits actin polymerization at the cell-cell
interface (figure 5 and 6) and sensitizes cells to extend cell
surface protrusions before completing a tube structure
(upper panel, figure 10). Therefore, it is a plausible
hypothesis that significant re-arrangements of actin
cytoskeleton pattern during tube formation triggers mem-
brane changes in ECs to protect the prima facie tube struc-
tures from the effects of excess growth factors and
Thalidomide attenuates NO mediated migration in ECs Figure 11
Thalidomide attenuates NO mediated migration in 
ECs: Scratching the EC monolayer with a sterile plastic 
scraper, a linear wound was made. The cells were incubated 
with 500 µmol SNP for 1 hour. The SNP treated cells were 
treated with thalidomide (25, 50, and 75 µg/ml) and incu-
bated for 8 hours. Images were taken at 0 and 8 hours after 
adding thalidomide to the cells. Quantification of the areas of 
the wounds was performed by using Scion Image, Release 
Alpha 4.0 3.2 and Adobe Photoshop version 6.0. The data 
depicts that rate of SNP mediated wound healing were 
slower by 50% and 85% in 50 and 75 µg/ml thalidomide 
treated cells respectively in comparison to that of control. 
Cells treated with 25 µg/ml thalidomide showed no signifi-
cant change in SNP mediated wound healing. The asterisks 
represent the level of significance. * P < 0.05 compared to 
control.
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Time-lapse imaging of thalidomide treated single EC tube  structure Figure 10
Time-lapse imaging of thalidomide treated single EC 
tube structure. The tube was treated with 500 µmol SNP 
at 15th minute to find any further effect on the tube struc-
ture. No effect of either thalidomide or SNP was observed 
on the structure and morphology of the tube and the cells as 
well. However, thalidomide blocked the formation of filopo-
dia, replacing them with broader protrusions on EC surface 
(arrows in the right panel).
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autacoids such as NO. This observation also supports the
concept that thalidomide restricts blood vessel formation
by inhibiting cellular proliferation and migration at the
single cell level before they organize into a tube or ring
like structure.
Dynamic rearrangement of the cytoskeleton is the key to
migration of the cells [32]. Signaling pathways attributed
to the migration of cells form a complex network of small
GTPase-driven local networks that ultimately converge
into the controlling nodes for actin polymerization pat-
tern in the down-stream events [33]. Signaling pathways
involving small GTPases and down stream activators such
as ROCK, cdc42, MLCK tune the actin polymerization pat-
tern in the cell membrane to define filopodia, a parallel
arrangements of F-actins and lamellipodia, a diagonal
arrangements of F-actins [21]. Dynamics of sub-cellular
actin polymerization defines the cell surface extensions
such as filopodia and lamellipodia structures, which are
crucial to cellular migration [34]. With respect to actin
polymerization, VEGF-treatment leads to rapid phospho-
rylation of actin, depolymerization factor cofilin, and its
upstream regulator, LIM-kinase (LIMK). Pharmacological
inhibitors of phosphoinositide-3 kinase (PI3-K) and the
rho-activated kinase (ROCK) attenuate VEGF-induced
LIMK phosphorylation that indicates a role for (PI3-K)
and ROCK in the signaling pathways leading to regulation
of LIMK activity [36]. We observed an altered phalloidin
staining pattern, which represents the actin polymeriza-
tion status of thalidomide treated ECs (figure 5 and 6).
The number of lamellipodia was reduced significantly in
thalidomide-treated cells while a strong pattern of central
microfilament and membrane dense actin plates
appeared in the cytosol and membrane respectively (fig-
ure 5). With respect to sub-cellular actin polymerization,
a recent publication suggests that the sub-cellular localiza-
tion of actin-related protein 2/3 (Arp2/3) complex, a
prime actin polymerization nucleator, is crucial to the
migration of the cells [36]. These observations prompt us
to speculate that thalidomide signals to downstream
effectors to impair migratory mechanisms of ECs by
changing the actin polymerization pattern during the ini-
tial phase of angiogenesis by blocking individual cells to
organize a tube like structure.
Does thalidomide cross-talk with NO downstream signal-
ing pathway to interfere with cellular migration? To check
the role of thalidomide in NO driven endothelial rear-
rangements we delivered NO via SNP prior to thalido-
mide treatments of the cells. We found that thalidomide
neutralizes NO induced changes in the cytoskeleton of
ECs (data not shown). This prima facie observation sup-
ports our hypothesis that thalidomide may cross talk with
Thalidomide arrested SNP mediated formation of extensions  inECs Figure 13
Thalidomide arrested SNP mediated formation of 
extensions inECs. The graph shows that SNP induced for-
mation of lamellipodia and filopodia in comparison to that of 
DMSO (control) treated cells (data not shown). A further 
challenge with 25, 50 and 75 µg/ml thalidomide caused a 
decrease in the number of lamellipodia and filopodia struc-
tures in comparison to that of SNP treated cells from 50 and 
75 µg/ml groups. SNP, Tx25, Tx50 and Tx75 denote 500 
µmol SNP, 25, 50 and 75 µg/ml thalidomide respectively. # 
and * represents the level of significance for the change of 
the number of filopodia and lamellipodia respectively when 
compared that with only SNP groups.
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Thalidomide induced expansion of SNP treated cells Figure 12
Thalidomide induced expansion of SNP treated cells. 
An increase in average cell area was observed in the cells 
treated with 50 and 75 µg/ml thalidomide in comparison to 
that of only SNP treated cells. SNP, Tx25, Tx50 and Tx75 
denote 500 µmol SNP, 25, 50 and 75 µg/ml thalidomide 
respectively. The asterisks represent the level of significance. 
* P < 0.05 compared to control.
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NO signaling pathway. Bioavailability and functions of
NO are critically controlled by the redox status of the sys-
tem [37]. Reports suggest that thalidomide enhances
superoxide anion release from human polymorphonu-
clear and mononuclear leukocytes [38]. Therefore, rela-
tionship of NO and thalidomide with other oxygen
species such as peroxynitrite, hydrogen peroxide, superox-
ide radicals and nitrite oxide would determine the nature
of cross talk between thalidomide and NO down stream
signaling. Recent reports claim that thalidomide exhibits
NOS-inhibitory activity [39]. Although the results of our
study support the thought of an interplay between thalid-
omide and NO downstream signaling pathway, it is pos-
sible that thalidomide exerts its anti-migratory effects, at
least in part, by inhibiting NOS at the NO upstream
events. The possible explanation is that inactivation of
NOS by thalidomide is associated with the re-localization
of NOS due to cytoskeletal rearrangements. Reorientation
of actin-based infra-structure could place NOS in discrete
membrane compartments or cytoplasmic regions causing
insufficient access to other signaling proteins, which are
responsible for NOS activation. There is an inverse rela-
tionship between the concentration of G-actin and eNOS
expression in endothelial cells subjected to pharmacolog-
ical alteration of their cytoskeleton [40]. The increase in
eNOS activity caused by G-actin was much higher than
that caused by F-actin [41]. However, our results docu-
ment a higher degree of polymerization of actin in thalid-
omide-treated cells, which lead to expanded cell surface
and perimeter as well (Figure 12). We speculate a possible
mechanism of thalidomide mediated blocking of NO
driven endothelial functions, which attributes, at least in
part, to the thalidomide associated cytoskeleton rear-
rangement causing NOS inactivation. Hence, results of
our present work strongly indicate that thalidomide
blocks NO driven endothelial functions by interfering
with the actin polymerization pattern of ECs. We deem
that thalidomide attenuates NO driven endothelial func-
tions, in part, in ECs by interplaying with the NO down
stream signaling molecules.
Conclusion
Present work evidences a novel cellular mechanism of tha-
lidomide mediated endothelial dysfunction, which
attributes to the altered pattern of EC migration. Further
investigation into the cause of thalidomide-mediated dis-
ruption in NO-induced EC migration shows that thalido-
Migration assay by using modified Boyden's chamber Figure 15
Migration assay by using modified Boyden's chamber: 
ECs were trypsinized and seeded on the upper chamber of 
Boyden's chamber, which is a twochamber system separated 
by a collagen coated 8-µm pore size polycarbonate mem-
branes. Lower well was filled with DMEM. The chambers 
were then incubated at 37°C, 5% CO2 for 3 h. Cells were 
migrated across the membrane and stuck to the lower part 
of the membrane. After the incubation, the polycarbonate 
membrane was fixed and stained with propidium iodide, a flu-
orescent nuclear probe. Cell number was counted before 
and after experiments to quantify the proliferation status of 
the loaded cells in Boyden's chamber. * P < 0.05 compared to 
only SNP treated cells.
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Thalidomide antagonized the formation SNP induced stress  fibers in ECs Figure 14
Thalidomide antagonized the formation SNP 
induced stress fibers in ECs. A SNP (500 µmol) treat-
ment induced stress fiber formation in ECs by two and a half 
fold in comparison to that of DMSO treated (control) cells. 
When SNP treated cells were challenged with 25, 50 and 75 
µg/ml thalidomide respectively, cells from the 50 and 75 µg/
ml thalidomide groups showed 30% and 50% drops in the 
number of stress fibers respectively in comparison to that of 
only SNP treated cells. SNP, Tx25, Tx50 and Tx75 denote 
500 µmol SNP, 25, 50 and 75 µg/ml thalidomide respectively. 
The asterisks represent the level of significance. * P < 0.05 
compared to only SNP treated cells.
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mide induces dose-dependent actin polymerization in EC
in the early phase of angiogenesis, which might be the
basic mechanism of the attenuation of angiogenesis. An
extended study aiming at the dissection of biochemical
signaling pathway, which will unravel the cross talk
between thalidomide and NO down stream signaling
would help to understand further the thalidomide actions
in endothelium, an area of immense clinical importance.
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Thalidomide reduces the sub-population of the SNP treated  cells with higher membrane actin polymerization pattern Figure 16
Thalidomide reduces the sub-population of the SNP 
treated cells with higher membrane actin polymeri-
zation pattern: Analysis of the images obtained from phal-
loidin experiments gives two sub-populations with varying 
fluorescent intensity of phalloidin 1) low intensity membrane 
pattern of actin polymerization described as Low AP and 2) 
Higher intensity of actin polymerization in the plasma mem-
brane described as High AP (upper panel). SNP treatments of 
ECs caused an increase in the number of high AP cells. Fur-
ther treatments of these cells with three concentrations of 
thalidomide (25, 50 and 75 µg/ml) reduced the number of 
high AP cells in a dose dependent manner. Particularly, 50 
and 75 µg/ml groups significantly reduced the high AP popu-
lation with a corresponding increase in low AP cells. SNP, 
Tx25, Tx50 and Tx75 denote 500 µmol SNP, 25, 50 and 75 
µg/ml thalidomide respectively. The asterisks represent the 
level of significance. * P < 0.05 compared to only SNP treated 
cells.
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